VIR

10.28

3.38% -0.36

Handel nachbörslich: 10.27 -0.010 -0.10%

Vir Biotechnology Inc (VIR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt VIR? Forum Prognose

Schlusskurs vom Vortag:

$10.64

Offen:

$10.71

24-Stunden-Volumen:

1.65M

Relative Volume:

0.51

Marktkapitalisierung:

$1.66B

Einnahmen:

$68.56M

Nettoeinkommen (Verlust:

$-437.99M

KGV:

-3.2492

EPS:

-3.1639

Netto-Cashflow:

$-396.61M

1W Leistung:

-5.08%

1M Leistung:

+22.38%

6M Leistung:

+59.88%

1J Leistung:

+68.52%

1-Tages-Spanne:

$10.17

$10.90

1-Wochen-Bereich:

$10.00

$10.96

52-Wochen-Spanne:

$4.155

$11.66

Vir Biotechnology Inc Stock (VIR) Company Profile

Firmenname

Vir Biotechnology Inc

Sektor

Healthcare (1107)

Branche

Biotechnology (620)

Telefon

415-906-4324

Adresse

1800 OWENS STREET, SAN FRANCISCO, CA

Mitarbeiter

367

Twitter

@Vir_Biotech

Nächster Verdiensttermin

2026-05-06

Neueste SEC-Einreichungen

VIR's Discussions on Twitter

Compare VIR vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VIR Vir Biotechnology Inc	10.28	1.72B	68.56M	-437.99M	-396.61M	-3.1639
VRTX Vertex Pharmaceuticals Inc	430.14	108.36B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	731.77	78.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	775.03	48.74B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	302.11	41.16B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	298.16	33.17B	5.36B	287.73M	924.18M	2.5229

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-24	Hochstufung	Raymond James	Outperform → Strong Buy
2025-09-03	Eingeleitet	Evercore ISI	Outperform
2025-08-27	Hochstufung	BofA Securities	Neutral → Buy
2024-01-29	Herabstufung	JP Morgan	Overweight → Neutral
2023-09-08	Herabstufung	BofA Securities	Buy → Neutral
2023-03-06	Hochstufung	JP Morgan	Neutral → Overweight
2023-02-21	Hochstufung	Goldman	Neutral → Buy
2023-01-27	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2022-09-14	Eingeleitet	SVB Leerink	Outperform
2022-09-09	Eingeleitet	Morgan Stanley	Underweight
2022-03-03	Hochstufung	Robert W. Baird	Underperform → Neutral
2021-12-21	Herabstufung	Robert W. Baird	Neutral → Underperform
2021-10-25	Hochstufung	JP Morgan	Underweight → Neutral
2021-09-22	Herabstufung	Goldman	Buy → Neutral
2021-06-04	Fortgesetzt	Robert W. Baird	Neutral
2021-01-27	Herabstufung	JP Morgan	Neutral → Underweight
2021-01-20	Bestätigt	H.C. Wainwright	Buy
2020-10-05	Eingeleitet	BofA Securities	Buy
2020-09-14	Hochstufung	Goldman	Neutral → Buy
2020-09-11	Hochstufung	JP Morgan	Underweight → Neutral
2020-08-20	Eingeleitet	Needham	Buy
2020-03-19	Herabstufung	JP Morgan	Neutral → Underweight
2020-03-13	Herabstufung	Goldman	Buy → Neutral
2020-02-27	Herabstufung	Robert W. Baird	Neutral → Underperform
2020-02-04	Herabstufung	JP Morgan	Overweight → Neutral
2019-11-14	Eingeleitet	Robert W. Baird	Neutral
2019-11-05	Eingeleitet	Barclays	Overweight
2019-11-05	Eingeleitet	Cowen	Outperform
2019-11-05	Eingeleitet	Goldman	Buy
2019-11-05	Eingeleitet	JP Morgan	Overweight

Alle ansehen

Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten

08:15 AM

Needham Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $18 - Moomoo

08:15 AM

03:11 AM

Certain Stock options of Vir Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 27-APR-2026. - marketscreener.com

Apr 26, 2026

Is VIR a Good Stock to Buy? - HarianBasis.co

Apr 26, 2026

Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now? - Insider Monkey

Apr 26, 2026

Apr 24, 2026

Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results - BioSpace

Apr 24, 2026

Apr 23, 2026

Press Release: Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results - 富途牛牛

Apr 23, 2026

Vir Biotechnology to release Q1 2026 earnings on May 6 ahead of investor call - Traders Union

Apr 23, 2026

Vir Biotechnology Marks Key Hepatitis B Milestone With Phase 2 Combo Study Update - TipRanks

Apr 23, 2026

Apr 22, 2026

Vir Biotechnology Expands Oncology Pipeline via Astellas Partnership - HarianBasis.co

Apr 22, 2026

Vir Biotechnology (VIR) Posts 80.98% Year-To-Date Growth - Insider Monkey

Apr 22, 2026

Apr 21, 2026

VIR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Apr 21, 2026

Vir Biotechnology (VIR) Is Up 19.1% After Astellas Cancer Pact Closes With $315M Inflows - simplywall.st

Apr 21, 2026

Vir Biotechnology Doses First Patient in Prostate Cancer Clinical Trial - HarianBasis.co

Apr 21, 2026

Apr 20, 2026

Vir Biotechnology stock hits 52-week high at $10.94 By Investing.com - Investing.com Australia

Apr 20, 2026

Vir Biotechnology (NASDAQ:VIR) Sets New 1-Year HighHere's Why - MarketBeat

Apr 20, 2026

Can Vir Biotechnology (VIR)’s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer? - insidermonkey.com

Apr 20, 2026

Vir Biotechnology stock hits 52-week high at $10.94 - Investing.com

Apr 20, 2026

Apr 19, 2026

Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In? - Insider Monkey

Apr 19, 2026

Apr 18, 2026

8 Best Low Priced Biotech Stocks to Invest In - Insider Monkey

Apr 18, 2026

Apr 16, 2026